X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Rama ...

November 9, 2023 | --- | --- | --- | --- | --- | --- | |--------------------------------------------------|----------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | PROGRESS | PATIENTS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Developing the first oral treatments for chronic | | | | | | | | | | | | | | neutropenic disorders | | | | | | | | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2023 Results Conference Call August 10, 2023 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim CMO Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Kristen Kluska - Cantor Fitzgerald Ted Tenthoff - Piper Sandler Mark Brown - Cowen and Company Mayank Mamtani - B. Riley RK - H.C. Wainwright Trevor Allred - Oppenheimer Operator Greetings. Welcome to X4 Pharmaceuticals' Secon ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call. [Operator Ins ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 _________________________________________________________________________________________________________ X4 PHARMACEUTICALS, INC. ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Conference Call March 21, 2023 9:00 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim Chief Medical Officer Mark Baldry - Chief Commercial Officer Conference Call Participants Divya Rao - TD Cowen Edward Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright Operator Thank you for standing by. This is the conference operator. Welcome to ...

Corporate Overview November 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or inten ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Diego Cadavid - Chief Medical Officer Mark Baldry - Chief Commercial Officer Murray Stewart - Interim Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Trevor Allred - Oppenheimer Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, ...